TY - JOUR
T1 - Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury
AU - TRACK-TBI Investigators
AU - Kulbe, Jacqueline R.
AU - Jain, Sonia
AU - Nelson, Lindsay D.
AU - Korley, Frederick K.
AU - Mukherjee, Pratik
AU - Sun, Xiaoying
AU - Okonkwo, David O.
AU - Giacino, Joseph T.
AU - Vassar, Mary J.
AU - Robertson, Claudia S.
AU - McCrea, Michael A.
AU - Wang, Kevin K.W.
AU - Temkin, Nancy
AU - Mac Donald, Christine L.
AU - Taylor, Sabrina R.
AU - Ferguson, Adam R.
AU - Markowitz, Amy J.
AU - Diaz-Arrastia, Ramon
AU - Manley, Geoffrey T.
AU - Stein, Murray B.
AU - Badjatia, Neeraj
AU - Duhaime, Ann Christine
AU - Feeser, V. Ramana
AU - Keene, C. Dirk
AU - Madden, Christopher
AU - Merchant, Randall
AU - Puccio, Ava
AU - Schnyer, David
AU - Taylor, Sabrina R.
AU - Valadka, Alex
AU - Yue, John K.
AU - Yuh, Esther L.
AU - Zafonte, Ross
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Several proteins have proven useful as blood-based biomarkers to assist in evaluation and management of traumatic brain injury (TBI). The objective of this study was to determine whether two day-of-injury blood-based biomarkers are predictive of posttraumatic stress disorder (PTSD). We used data from 1143 individuals with mild TBI (mTBI; defined as admission Glasgow Coma Scale [GCS] score 13–15) enrolled in TRACK-TBI, a prospective longitudinal study of level 1 trauma center patients. Plasma glial fibrillary acidic protein (GFAP) and serum high sensitivity C-reactive protein (hsCRP) were measured from blood collected within 24 h of injury. Two hundred and twenty-seven (19.9% of) patients had probable PTSD (PCL-5 score ≥ 33) at 6 months post-injury. GFAP levels were positively associated (Spearman’s rho = 0.35, p < 0.001) with duration of posttraumatic amnesia (PTA). There was an inverse association between PTSD and (log)GFAP (adjusted OR = 0.85, 95% CI 0.77–0.95 per log unit increase) levels, but no significant association with (log)hsCRP (adjusted OR = 1.11, 95% CI 0.98–1.25 per log unit increase) levels. Elevated day-of-injury plasma GFAP, a biomarker of glial reactivity, is associated with reduced risk of PTSD after mTBI. This finding merits replication and additional studies to determine a possible neurocognitive basis for this relationship.
AB - Several proteins have proven useful as blood-based biomarkers to assist in evaluation and management of traumatic brain injury (TBI). The objective of this study was to determine whether two day-of-injury blood-based biomarkers are predictive of posttraumatic stress disorder (PTSD). We used data from 1143 individuals with mild TBI (mTBI; defined as admission Glasgow Coma Scale [GCS] score 13–15) enrolled in TRACK-TBI, a prospective longitudinal study of level 1 trauma center patients. Plasma glial fibrillary acidic protein (GFAP) and serum high sensitivity C-reactive protein (hsCRP) were measured from blood collected within 24 h of injury. Two hundred and twenty-seven (19.9% of) patients had probable PTSD (PCL-5 score ≥ 33) at 6 months post-injury. GFAP levels were positively associated (Spearman’s rho = 0.35, p < 0.001) with duration of posttraumatic amnesia (PTA). There was an inverse association between PTSD and (log)GFAP (adjusted OR = 0.85, 95% CI 0.77–0.95 per log unit increase) levels, but no significant association with (log)hsCRP (adjusted OR = 1.11, 95% CI 0.98–1.25 per log unit increase) levels. Elevated day-of-injury plasma GFAP, a biomarker of glial reactivity, is associated with reduced risk of PTSD after mTBI. This finding merits replication and additional studies to determine a possible neurocognitive basis for this relationship.
UR - http://www.scopus.com/inward/record.url?scp=85133715846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133715846&partnerID=8YFLogxK
U2 - 10.1038/s41386-022-01359-5
DO - 10.1038/s41386-022-01359-5
M3 - Article
C2 - 35717463
AN - SCOPUS:85133715846
SN - 0893-133X
VL - 47
SP - 2300
EP - 2308
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 13
ER -